Browse HBG2

Summary
SymbolHBG2
Namehemoglobin, gamma G
Aliases HBG-T1; TNCY; G-gamma globin Paulinia; abnormal hemoglobin; gamma-2-globin; hb F Ggamma; hemoglobin gamma-2 ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00042 Globin
Function

Gamma chains make up the fetal hemoglobin F, in combination with alpha chains.

> Gene Ontology
 
Biological Process GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0015669 gas transport
GO:0015671 oxygen transport
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
Molecular Function GO:0005344 oxygen transporter activity
GO:0005506 iron ion binding
GO:0019825 oxygen binding
GO:0020037 heme binding
GO:0046906 tetrapyrrole binding
Cellular Component GO:0005833 hemoglobin complex
GO:0044445 cytosolic part
GO:0072562 blood microparticle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-109582: Hemostasis
Summary
SymbolHBG2
Namehemoglobin, gamma G
Aliases HBG-T1; TNCY; G-gamma globin Paulinia; abnormal hemoglobin; gamma-2-globin; hb F Ggamma; hemoglobin gamma-2 ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HBG2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolHBG2
Namehemoglobin, gamma G
Aliases HBG-T1; TNCY; G-gamma globin Paulinia; abnormal hemoglobin; gamma-2-globin; hb F Ggamma; hemoglobin gamma-2 ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HBG2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHBG2
Namehemoglobin, gamma G
Aliases HBG-T1; TNCY; G-gamma globin Paulinia; abnormal hemoglobin; gamma-2-globin; hb F Ggamma; hemoglobin gamma-2 ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HBG2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.330.475
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0270.972
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5580.402
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.0680.125
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8940.414
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2870.299
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.7430.049
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.1340.372
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-2.1460.147
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.4120.861
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-3.4060.286
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1360.725
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HBG2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91633.3258.30.673
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 594033.36.71
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHBG2
Namehemoglobin, gamma G
Aliases HBG-T1; TNCY; G-gamma globin Paulinia; abnormal hemoglobin; gamma-2-globin; hb F Ggamma; hemoglobin gamma-2 ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HBG2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHBG2
Namehemoglobin, gamma G
Aliases HBG-T1; TNCY; G-gamma globin Paulinia; abnormal hemoglobin; gamma-2-globin; hb F Ggamma; hemoglobin gamma-2 ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HBG2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HBG2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHBG2
Namehemoglobin, gamma G
Aliases HBG-T1; TNCY; G-gamma globin Paulinia; abnormal hemoglobin; gamma-2-globin; hb F Ggamma; hemoglobin gamma-2 ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HBG2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHBG2
Namehemoglobin, gamma G
Aliases HBG-T1; TNCY; G-gamma globin Paulinia; abnormal hemoglobin; gamma-2-globin; hb F Ggamma; hemoglobin gamma-2 ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HBG2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHBG2
Namehemoglobin, gamma G
Aliases HBG-T1; TNCY; G-gamma globin Paulinia; abnormal hemoglobin; gamma-2-globin; hb F Ggamma; hemoglobin gamma-2 ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HBG2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHBG2
Namehemoglobin, gamma G
Aliases HBG-T1; TNCY; G-gamma globin Paulinia; abnormal hemoglobin; gamma-2-globin; hb F Ggamma; hemoglobin gamma-2 ......
Chromosomal Location11p15.5
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HBG2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.